Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Amgen (NASDAQ: AMGN) and …
"But giving the way the stock is reacting, maybe we're coming close to finding a bottom here." In the technology sector, Brady said Nokia has good fundamentals, so he's inclined to hold onto Nokia. He also said Amgen is a terrific company …
Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $180.12 to a high of $183.40. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $181.25 on volume of 792,000 …
Novartis has obtained the marketing rights for Luxterna oustide the United States thereby building upon its gene therapy treatments which includes Kymriah.
By Mr. Loeb’s reckoning, a breakup could yield significant results. Given its current corporate self-help plan, Amgen appears set to improve its stock’s valuation to $189 a share by the end of 2016. But if the company splits itself in two, …
traders are definitely monitoring Bristol-Myers Squibb’s price action to see if this move attracts further buying into the stock. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that develops, …